Next Issue
Volume 6, August
Previous Issue
Volume 6, January
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 6, Issue 2 (April 2014) – 5 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
6 pages, 752 KiB  
Article
Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-Lymphocyte Clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas
by Giovanni Carulli, Virginia Ottaviano, Valentina Guerri, Stefano Giuntini, Paola Sammuri, Eugenio M. Ciancia and Antonio Azzarà
Hematol. Rep. 2014, 6(2), 5381; https://doi.org/10.4081/hr.2014.5381 - 26 Jun 2014
Cited by 5 | Viewed by 504
Abstract
Hematogones are precursors of B-lymphocytes detected in small numbers in the bone marrow. Flow cytometry is the most useful tool to identify hematogones and, so far, 4-color methods have been published. In addition, flow cytometry is used in the diagnosis and follow-up of [...] Read more.
Hematogones are precursors of B-lymphocytes detected in small numbers in the bone marrow. Flow cytometry is the most useful tool to identify hematogones and, so far, 4-color methods have been published. In addition, flow cytometry is used in the diagnosis and follow-up of lymphomas. We developed a flow cytometric 7-color method to enumerate hematogones and to assess B-lymphocyte clonality for routine purposes. We evaluated 171 cases of B-cell non-Hodgkin lymphomas, either at diagnosis or in the course of follow-up. By our diagnostic method, which was carried out by the combination K/λ/CD20/CD19/CD10/CD45/CD5, we were able to detect hematogones in 97.6% of samples and to distinguish normal B-lymphocytes, neoplastic lymphocytes and hematogones in a single step. The percentage of hematogones showed a significant inverse correlation with the degree of neoplastic infiltration and, when bone marrow samples not involved by disease were taken into consideration, resulted higher in patients during follow-up than in patients evaluated at diagnosis. Full article
5 pages, 732 KiB  
Article
Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study
by Steven M. Chan, John Chadwick, Daniel L. Young, Elizabeth Holmes and Jason Gotlib
Hematol. Rep. 2014, 6(2), 5466; https://doi.org/10.4081/hr.2014.5466 - 23 Jun 2014
Cited by 7 | Viewed by 896
Abstract
Neutropenic fever (NF) is a life-threatening complication of myelosuppressive chemotherapy in patients with hematologic malignancies and triggers the administration of broad-spectrum antimicrobials. The ability to accurately predict NF would permit initiation of antimicrobials earlier in the course of infection with the goal of [...] Read more.
Neutropenic fever (NF) is a life-threatening complication of myelosuppressive chemotherapy in patients with hematologic malignancies and triggers the administration of broad-spectrum antimicrobials. The ability to accurately predict NF would permit initiation of antimicrobials earlier in the course of infection with the goal of decreasing morbid complications and progression to septic shock and death. Changes in the blood level of inflammatory biomarkers may precede the occurrence of NF. To identify potential biomarkers for the prediction of NF, we performed serial meas- urements of nine biomarkers [C-reactive protein (CRP), protein C, interleukin (IL)-6, IL-8, IL-10, IL-1β, tumor necrosis factor-α, monocyte chemotactic protein-1, and intercellular adhesion molecule-1] using a multiplex ELISA array platform every 6-8 hours in patients undergoing myelosuppressive chemotherapy for hematologic malignancies. We found that the blood levels of IL-6 and CRP increased significantly 24 to 48 hours prior to the onset of fever. In addition, we showed that frequent biomarker monitoring is feasible using a bedside micro sample test device. The results of this pilot study suggest that serial monitoring of IL-6 and CRP levels using a bedside device may be useful in the prediction of NF. Prospective studies involving a larger cohort of patients to validate this observation are warranted. This trial is registered at ClinicalTrials.gov (NCT01144793). Full article
2 pages, 548 KiB  
Article
Hemophagocytic Lymphohistiocytosis and Pelger-Huët Anomaly Associated with Colchicine Intoxication
by Baris Malbora, Emine Polat and Sare Gulfem Akyuz
Hematol. Rep. 2014, 6(2), 5356; https://doi.org/10.4081/hr.2014.5356 - 19 Jun 2014
Cited by 4 | Viewed by 370
Abstract
Colchicine is frequently used in the treatment of familial Mediterranean fever (FMF). First symptoms of colchicine intoxication are gastrointestinal disturbances, such as abdominal cramps, diarrhea, pancytopenia and so on. Herein, we report a female FMF patient with pancytopenia and hemophagocytic lymphohitiocytosis (HLH), following [...] Read more.
Colchicine is frequently used in the treatment of familial Mediterranean fever (FMF). First symptoms of colchicine intoxication are gastrointestinal disturbances, such as abdominal cramps, diarrhea, pancytopenia and so on. Herein, we report a female FMF patient with pancytopenia and hemophagocytic lymphohitiocytosis (HLH), following colchicine intoxication for committing suicide. To our knowledge, this is the first reported case of a patient with HLH associated with colchicine intoxication. Full article
2 pages, 526 KiB  
Case Report
Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
by David Sanford, Maria MacDonald, Michael Nicolle and Anargyros Xenocostas
Hematol. Rep. 2014, 6(2), 5288; https://doi.org/10.4081/hr.2014.5288 (registering DOI) - 19 Jun 2014
Cited by 7 | Viewed by 265
Abstract
We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase [...] Read more.
We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required. Full article
3 pages, 613 KiB  
Article
Prevalence of Thrombophilic Gene Polymorphisms in an Azari Population of Iran
by Nasrin Bargahi, Malak Farajzadeh, Ahmad Poursadegh-Zonouzi and Davoud Farajzadeh
Hematol. Rep. 2014, 6(2), 5321; https://doi.org/10.4081/hr.2014.5321 - 22 Apr 2014
Cited by 5 | Viewed by 441
Abstract
There is several evidence suggests that thrombophilic gene polymorphisms may influence susceptibility to thromboembolic events. The prevalence of these polymorphisms is different in various races and ethnics. Accordingly, we studied the prevalence of Factor V (G1691A and A4070G), prothrombin G20210A and PAI-1 4G/5G [...] Read more.
There is several evidence suggests that thrombophilic gene polymorphisms may influence susceptibility to thromboembolic events. The prevalence of these polymorphisms is different in various races and ethnics. Accordingly, we studied the prevalence of Factor V (G1691A and A4070G), prothrombin G20210A and PAI-1 4G/5G in healthy northwest population of Iran. In this prospective study, 500 healthy individuals, who had no history of both personal and family history of thromboembolic disorders, were selected as a sample of healthy population in northwestern Iran. Genotyping of these polymorphisms was performed using the amplification refractory mutation system-polymerase chain reaction method. No significant differences were detected between the expected and observed frequencies of FV G1691A and A4070G, prothrombin G20210A polymorphisms (p > 0.05), while the expected frequency of 4G allele was significantly more than observed frequency in the studied population (p < 0.01). These findings were compared with other reports from various populations. In conclusion, the allele frequency for FV G1691A and PAI-1 4G/5G polymorphisms showed relative consistency compared to those of previous studies, while the incidence pattern of FV A4070G polymorphism in Northwestern population of Iran showed conflicting results regarding other studied population. The prothrombin G20210A polymorphism was observed at a higher frequency than other studied populations. Full article
Previous Issue
Next Issue
Back to TopTop